CytoMed Therapeutics Limited (GDTC) vs Satellos Bioscience Inc. (MSLE)

A side-by-side comparison of CytoMed Therapeutics Limited and Satellos Bioscience Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

GDTC

CytoMed Therapeutics Limited

$11M

$0.89HealthcareDelayed quote: Oct 6, 2026, 12:53 PM EDT

MSLE

Satellos Bioscience Inc.

$10M

$8.09HealthcareDelayed quote: Oct 6, 2026, 12:51 PM EDT

Total return — GDTC vs MSLE

growth of $100 · dividends reinvested · last 1y

GDTC -18.5% (-18.5%/yr)MSLE +13.7% (+13.7%/yr)MSLE compounded faster over this window

GDTC MSLE

Metrics side by side

Total return (annualized)

Metric	GDTC	MSLE
Total return (1Y)	-49.59%	N/A
Total return CAGR (3Y)	-34.77%	N/A

GDTC is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full GDTC analysis Full MSLE analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.